Alvogen has been selected as the preferred bidder for acquisition of DreamPharma

Published: 2014-07-07 13:59:23

Updated: 2014-07-07 13:59:23

Alvogen has been selected as the preferred bidder for acquisition of DreamPharma.

On July 4, according to the pharmaceutical industry, Hanwha Chemical and Citigroup Global Markets Securities selected Alvogen as the proffered bidder for acquisition of DreamPharma.

Alvogen is a global generic company which took over Kunwha Pharmaceutical in 2012 and entered into domestic market. It surpassed Ah...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.